Haloperidol serum concentrations in critically ill patients included in the REDUCE study
ICU delirium occurs frequently and is associated with unfavorable outcome. A recent delirium prevention study, the REDUCE study, has assessed the efficacy of prophylactic use of haloperidol . This study showed no effect for any group for any outcome . It is unknown if serum levels of haloperidol are related to the effect of haloperidol in prevention or treatment of ICU-acquired delirium. Therapeutic serum levels of haloperidol for treatment of schizophrenia are reported to be 3–20 µg/L [2, 3]. We pre-planned to determine haloperidol serum concentrations in ICU patients receiving prophylactic haloperidol in the REDUCE study.
Methods and results
We included consecutive patients participating in the REDUCE study in one particular ICU. Haloperidol 3 × 1 mg and 3 × 2 mg daily and a placebo group were compared. A blood sample was drawn immediately before the third dose of study medication. This haloperidol trough serum level was assessed by a liquid...
Compliance with ethical standards
Conflict of interest
None of the authors have any conflict of interest.
- 2.Nederlandse Vereniging van Ziekenhuisapothekers (2006) Therapeutic drug monitoring: haloperidol. http://tdm-monografie.org/Media/Default/Monografieen/TDM%20Haloperidol%20210206.pdf. Accessed 23 Aug 2018.
- 3.Chernecky CC, Berger BJ (2007) Laboratory tests and diagnostic procedures. Elsevier, AmsterdamGoogle Scholar